In contrast to the HER2-0 carcinomas, the HER2-low carcinomas are diagnosed at a higher median age, more frequently occur in postmenopausal population, and are linked to more T1 tumors, higher N1 staging, worse histologic grading, and higher Ki-67 index. This evidence concerns the gene ERBB2 and carcinoma.